Skip to main content
ARS Home » Research » Publications at this Location » Publication #430946
Research Project: Intervention Strategies to Prevent and Control Crimean-Congo Hemorrhagic Fever (CCHF)

Location: Location not imported yet.

Title: Durable humoral immunity and long-term protection induced by a Crimean-Congo hemorrhagic fever virus replicon particle vaccine in mice

Author
item SORVILLO, TERESA - Centers For Disease Control And Prevention (CDC) - United States
item KARAASLAN, ELIF - Centers For Disease Control And Prevention (CDC) - United States
item DAVIES, KATHERINE - Oak Ridge Institute For Science And Education (ORISE)
item WELCH, STEPHEN - Centers For Disease Control And Prevention (CDC) - United States
item SCHOLTE, FLORINE - Centers For Disease Control And Prevention (CDC) - United States
item COLEMAN-MCCRAY, JOANN - Centers For Disease Control And Prevention (CDC) - United States
item AIDA-FICKEN, VIRGINIA - Centers For Disease Control And Prevention (CDC) - United States
item PEGAN, SCOTT - University Of California
item SPIROPOULOU, CHRISTINA - Centers For Disease Control And Prevention (CDC) - United States
item SPENGLER, JESSICA - Centers For Disease Control And Prevention (CDC) - United States
item BERGERON, ERIC - Centers For Disease Control And Prevention (CDC) - United States
item MONTGOMERY, JOEL - Centers For Disease Control And Prevention (CDC) - United States

Submitted to: NPJ Vaccines
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 10/9/2025
Publication Date: 11/21/2025
Citation: Sorvillo, T.E., Karaaslan, E., Davies, K.A., Welch, S.R., Scholte, F.E., Coleman-Mccray, J.D., Aida-Ficken, V., Pegan, S.D., Spiropoulou, C.F., Spengler, J.R., Bergeron, E., Montgomery, J.M. 2025. Durable humoral immunity and long-term protection induced by a Crimean-Congo hemorrhagic fever virus replicon particle vaccine in mice. NPJ Vaccines. 10. Article 244. https://doi.org/10.1038/s41541-025-01293-9.
DOI: https://doi.org/10.1038/s41541-025-01293-9

Interpretive Summary: This study evaluates the durability of a replicon particle vaccine against CCHFV in mice, to understand long-term protection and efficacy. This work demonstrated that the vaccine induced immune response remain for up to 18 months and protection of up to 75% can be achieved for 6 months after one dose, and 12 months after two doses. These findings demonstrate that the CCHFV replicon particle vaccine can generate durable immunity, with booster offering increased protection long-term.

Technical Abstract: A Crimean-Congo hemorrhagic fever virus replicon particle vaccine was evaluated for long-term immunity and efficacy in mice. IgG responses persisted up to 18 months, with similar titers across dosing strategies through 12 months. Protective efficacy reached =75% at 6 months (prime-only) and up to 12 months (prime-boost). Booster dosing enhanced antibody avidity, effector function, and improved long-term protection. These findings support durable immunity from single or boosted vaccination.